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Abstract
Aims Chronic non-viral myocarditis, also called inflammatory cardiomyopathy, can be treated with immune suppression on
tops of optimal medical therapy (OMT) for heart failure, using a combination of prednisolone and azathioprine (IPA). However,
there has been inconsistency in the effects of immunosuppression treatment. This meta-analysis is the first to evaluate all
available data of the effect of this treatment on left ventricular ejection fraction (LVEF) and the combined clinical endpoint
of cardiovascular mortality and/or heart transplantation-free survival.
Methods and results All trials with using IPA vs. OMT in this syndrome were searched using OVID Medline and ClinicalTrials.
gov, following the PRISMA guidelines. Missing data were retrieved after contacting the corresponding authors. All data was
reviewed and analysed using and standard meta-analysis methods. A random effect model was used to pool the effect sizes.
A total of four trials (three randomised controlled trials and one propensity-matched retrospective registry) including 369 pa-
tients were identified. IPA on top of OMT did not improve LVEF [mean difference 9.9% (95% confidence interval 1.8, 21.7)]
with significant heterogeneity. When we limited our pooled estimate to the published studies only, significant LVEF improve-
ment by IPA was observed [14% (1.4, 26.6)]. No cardiovascular mortality benefit was observed with the intervention [risk ratio
0.34 (0.08, 1.51)].
Conclusions At the moment, there is insufficient evidence supporting functional and prognostic benefits of IPA added to
OMT in virus negative inflammatory positive cardiomyopathy. Further adequate-powered well-designed prospective RCTs
should be warranted to explore the potential effects of adding immunosuppressive therapy to OMT.
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Introduction
Heart failure (HF) is a complex clinical syndrome, which pos-
sess a severe burden upon patients and health care systems
because of decreased quality of life, frequent hospital admis-
sions, mortality, and increasing health care resources
utilisation.1
Although HF with reduced ejection fraction (HFrEF) can be
sub categorised into ischemic and non-ischemic aetiology,
this difference is not reflected in the current guidelines on
HF treatment.2
However, for a certain portion of patients with HFrEF and
persistent symptoms despite optimal guideline-based medi-
cal treatment (OMT), there is a potential therapeutic
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intervention whereby immunosuppressive therapy can im-
prove left ventricular ejection fraction (LVEF) if the HF syn-
drome is because of chronic non-viral inflammation.3,4 This
entity is referred as ‘auto-immune’ or ‘inflammation positive
virus negative’ chronic myocarditis.
Pathophysiology of an inflammatory cardiomyopathy can
be very diverse, ranging from auto-immune, toxic to
infectious.5 Only studies conducted in non-fulminant non-
viral myocarditis or auto-immune myocarditis are included
in this meta-analysis. This syndrome is thought to be caused
by an intrinsic auto-immune disease, yet research has dem-
onstrated that an initial viral myocarditis can also trigger
pathological persistent myocardial inflammation even after
the virus has been cleared.6 Regulatory T-cells have been
shown to play a key role in controlling the immune response
in viral myocarditis.7 The role of genetic susceptibility to de-
velop a pathological response in viral myocarditis that can ul-
timately causes HF has been suspected in animal models.8
The rationale of using immunosuppression in inflammatory
cardiomyopathies is to halt the adverse innate immune re-
sponse that causes the HF syndrome in these patients.
There has been inconsistency in the effect of immunosup-
pression treatment.3–16 A recent systematic review17 showed
that recent two randomised controlled trials (RCTs) with a
combination therapy of prednisolone plus azathioprine dem-
onstrated improvement in LVEF. In addition, a large
propensity-matched registry data has demonstrated for the
first time prognostic improvement with the combination
therapy.16
A systematic review and meta-analysis of trials using a
combination of immune suppressive therapy with prednisone
and azathioprine (IPA) to treat HF refractory to OMT caused
by chronic non-fulminant virus negative or ‘autoimmune’
myocarditis was conducted to demonstrate the effect on
LVEF and HF events.
Methods
Identification and selection of studies
Protocol and registration
The systematic review and meta-analysis adhered to the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines for meta-analyses of in-
terventional studies and its checklist.18 Our systematic review
was prospectively registered to PROSPERO
(CRD42018100902, https://www.crd.york.ac.uk/PROSPERO/
display_record.php?RecordID=100902.).19
Eligibility criteria
Based on our hypothesis, studies were included when they
satisfied the following criteria: (i) (P) adults patients
(>16 years old) with biopsy-proven non-infective
inflammatory cardiomyopathy (defined as auto-immune or
virus negative/inflammation positive) AND LVEF <50% despite
OMT for >3 months. (ii) (I) Intervention with prednisone and
azathioprine on top of the standard HF care. (iii) (C) Control
group with standard HF care only. (iv) (O) Primary outcome
as the change in LVEF. The secondary outcome was cardio-
vascular mortality or HTx. (v) (S) RCTs or observational studies
including registries if they have a control group.
Information sources and search
We searched OVID MEDLINE and ClinicalTrials.gov from Janu-
ary 1950 till June 2018. The search terms used were: ‘cardio-
myopathy’, ‘myocarditis’, ‘immunosuppressive agents’,
‘steroids’, ‘prednisone’, and ‘azathioprine’, using Mesh terms
and including text search. Full details of search strategies
used are presented in Appendix A. We restricted our search
to human studies only (no animal experiments) with English
only (language restriction). We also searched on cinicaltrials.
gov for ongoing or aborted studies and contacted study au-
thors directly when necessary.
Study selection
Identified articles via electronic database search were
screened by the title and abstract level for pertinence by four
independent investigators (ABP, PT, KN, and OA). Based on
the previous negative findings,9,10 we excluded those with a
single agent intervention with either prednisone or azathio-
prine only. Remained articles were examined for inclusion
based on the above a priori determined criteria with
full-text reading. Review articles, editorials, letters, case re-
ports, and case series without control were also excluded.
Data extraction
Data collection process
Data were extracted as independently by the four investiga-
tors using a dedicated data-extraction form.
Data items
We collected the information on patient characteristics, trial
design, intervention details, and outcomes (Table 1). We also
searched the ‘study rationale and method papers’ of selected
trials to retrieve further details.21 Our primary outcome was
the changes in LVEF. The secondary outcome was cardiovas-
cular mortality or heart transplantation free survival/HTx.
When the selected outcomes were not reported in the origi-
nal reports, we contacted the authors, who kindly shared the
information with us.3,4,16
Risk of bias
Risk of bias in individual studies
We evaluated risks of bias at the study level using dedicated
tools for randomised (RoB 2.0) and non-randomised
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intervention (ROBINS-I in non-randomised studies).20,22,23 We
extracted information on (i) randomisation, (ii) deviations
from planned interventions, (iii) missing data, (iv) assessment
methods for the endpoint, and (v) choice of reported results.
Also, we performed a quality assessment for the trial registra-
tion protocol and study design.21 The information was used
to divide the studies for subgroup analysis in data synthesis
when meaningful.
Risk of bias across studies
Publication bias was assessed visually using funnel plots.
Qualitative analysis
Summary measures
Mean differences (MDs) were used for assessing the change
in LVEF and risk ratios (RRs) for binary outcomes, both with
their 95% confidence intervals (CIs).
Synthesis of results
The pooled MD and RR were calculated using a random ef-
fects model; DerSimonian–Laird method24 because we as-
sumed that the true effect sizes for these studies would be
distributed around a mean, instead of the fixed true value.
Heterogeneity was assessed using I2 and Cochran Q tests.
‘I2 values of 25%, 50%, and 75% were considered low, moder-
ate, and high levels of heterogeneity, respectively’27. A
Cochran Q P-value of <0.05 was considered significant, indi-
cating heterogeneity.
Additional analysis
Prespecified subgroup analysis was conducted, dividing stud-
ies based on the studies design (RCT or not), publication sta-
tus (published or not). A meta-regression was not performed
because less than 10 studies were identified.
Statistical analysis, including testing for heterogeneity and
publication bias, was performed using STATA version 15.1
Table 1 Baseline characteristics of included studies
Study Wojnicz Frustaci CZECH-ICITa Merken
Year 2001 2009 2013 2018
Study design RCT RCT RCT Registry with matched control
group
LVEF inclusion threshold
(%)
<40 <40 <40 Not requiredb
Duration of symptoms
(months)
>6 m >6 m >6 m >6 m
NYHA class II–IV II–IV ≥II I–IV
Clinical FU (months) 24 10–72 12b 15–47
Sample size 84 85 20 180
Mean age (years) 40 43 NA 49
LVEF baseline (%)
Control 23.8 ± 8.6 27.7 ± 6.4 22.2 ± 3.7 33 ± 14
Intervention 24.9 ± 7.3 26.5 ± 6.6 22.3 ± 4.7 31 ± 12
Atrial fibrillation (%) 30 NA NA 15
Left bundle branch block
(%)
NA 16 NA 20
IPA: prednisone
Starting dose 1 mg/kg/day for 12 days ·Arm A: Wojnicz
protocol
·Arm A: Wojnicz
protocol
·1 mg/kg/day for 4 weeks
Maintenance dose ·Every 5 days, tapered by 5 mg to
0,2 mg/day
·Arm B: Frustaci
protocol
·Arm B: Frustaci
protocol
·0,33 mg/kg/day afterwards
IPA: azathioprine (mg/kg/
day)
1 mg/kg/day 2 mg/kg/day 1–2 mg/kg/day 2 mg/kg/day
IPA: total duration
(months)
3 m 6 mc 3–6 m 6 md
Primary outcome Mortality, HTx, or HF readmission Change in LVEF Change in LVEF Mortality or HTx
Result primary outcome Negative Positive Negative Positive
Secondary outcome Change in LVEF Mortality or HTx Clinical events Change in LVEF
Result secondary outcomePositive Negative Negative Positive
aThis is a preliminary data from CZECH-ICIT (Czech Inflammatory Cardiomyopathy Immunosuppression Trial). Data on LVEF on baseline
and 6 months FU and clinical events at 24 months were obtained via direct communication with the authors. Details are provided in table
2 (cf. Appendix).
bMerken et al. used European Society of Cardiology (ESC) criteria for myocarditis20 which does not include any criteria for LVEF.
cThree patients received continuation of azathioprine after 6 months because of persistent/recurrent myocardial inflammation at
follow-up biopsy at 6 months—a prespecified follow-up procedure.
dDepending on the immunologic profile, cyclosporine was added in 11 patients for at least 6 months.
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(StataCorp LLC, TX, USA) using the ‘metan’, ‘funnel’, and
‘confunnel’ packages. A P-value of <0.05 was considered sta-
tistically significant.
Results
Identified and eligible studies (study selection)
The process of article selection based on PRISMA guidelines
(PRISMA flow chart) is presented in Figure 1. A total of 121
articles were identified via the database search (MEDLINE
and Clinical Trials.gov), and additional 10 studies were from
the previous report18 (which initially identified 8087 articles
via PubMed (n = 4823), Embase (n = 2830), LILAC (n = 294),
and Cochrane library (n = 140) by the search until January
2016). There were no duplicates. The titles and abstracts of
131 articles were screened for eligibility. Among them, 110
were included and assessed by full text, and 106 were ex-
cluded because of the following reasons: case report
(n = 59), Letter/editorial (n = 2), reviews (n = 5), and not ful-
filling our PICO (n = 40). A total of four articles (369 patients)
were eligible for the qualitative synthesis and meta-analysis.
Characteristics of included studies
Baseline demographics of the four included studies are
summarised in Table 1. Two of them were published RCTs,3,4
Figure 1 PRISMA flow chart.
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one was a published registry with a corresponding control
group,16 and one with aborted RCT without publication.21
Their populations were small to mid in size between 2021
and 18016 with a total of 369 patients. The participants were
all adults with biopsy-proven inflammatory cardiomyopathy,
and received either of additional IPA to standard HF care,
or standard HF care only. All of them had HF symptoms for
more than 6 months before the enrolment of the study but
one study,16 which included 53 patients (29%) with NYHA
class I at the time of enrolment. Follow-up periods were dif-
ferent for LVEF assessment and clinical endpoints. LVEF was
measured after 6 months in the RCTs3,4,21 and 12 months in
the registry.16 Because there is no evidence of any further in-
crease in left LVEF beyond 6months after treatment in the in-
dividual trials,3,4 the FU value was chosen at 6 months.
Cardiovascular endpoints were either mortality or HTx. Both
the Frustaci and Wojnicz group assessed the endpoints at
2 years after initiation of therapy; in the Merken registry,
the time window of clinical follow-up was less well defined
(median 31 months, range 15–47). All endpoints were
assessed together in the present analysis, regardless of
timing.
Weighted mean EF at baseline was 23% (range 22–32%).
For the secondary outcome, three studies had statistically
non-significant results, but one study showed statistically
significant favourable prognostic effect.16 The total
number of events was small [n = 33 (9.6%)], which yielded
wide CIs.
Risk of bias within studies
All four selected studies underwent critical appraisal using
tools according to study design by all four investigators indi-
vidually. Upon disagreement, consensus was reached after
careful deliberation.
The summary of risk of bias about 3 RCTs is presented in
Appendix B with detailed comments. First, for randomisation,
all three RCTs used true random processes to generate study
groups. However, only two of them reported information on
allocation concealment,3,4 resulting two studies with low risk
of bias and one study with high risk of bias. In the next step,
the deviations from intended interventions were reviewed,
and all were deemed low risk of bias. While all clinical
follow-up data were available from Wojnicz et al., some of
the echocardiographic data were missing. Regarding mea-
surement of the outcome, one had high risk of bias because
of open-label study design3 whereas the rest two had low risk
of bias. Finally, all selected RCTs had low risk in the selection
of the reported result category. To conclude, the overall risk
of bias was one with low risk,4 another with some concerns,3
and one with high risk of bias given limited access to the in-
formation because of unpublished nature.21
The risk of bias of the sole non-randomised intervention
study16 had four ‘low’ and three ‘moderate’ risks out of seven
components of bias assessment by ROBINS-I in
non-randomised studies template (Appendix C). The overall
bias assessment of this study was judged as ‘moderate’ given
choice of immunosuppression therapy in the treatment
group is not stated, but baseline characteristics were
matched. There was likely significant bias for echocardio-
graphic measurements because both patients and operators
were not blinded.
Risk of bias across studies
Both ordinary funnel and confunnel plots were used to assess
the publication bias among studies (Figure 2). Significant
asymmetric distributions of studies were observed in the
change in LVEF in both funnel and confunnel plots. The distri-
bution of the CV endpoints was showed small but obvious
asymmetry. Studies with a larger standard error with border-
line to negative effects were missing. Because of the low
number of studies, the funnel plots are only indicative of po-
tential bias.
Meta-analysis
The change in left ventricular ejection fraction
Among four identified studies, all showed a significant im-
provement in LVEF (with a maximum increase of 25.5%4 ex-
cept one,21 which yielded a statistically neutral result with
deterioration by the point estimate of 3.4% [95% CI 11,
4.6]. Pooled mean difference in LVEF was 9.9% [1.8, 21.7]
(Figure 3A). Because there was significant heterogeneity (I2
96.8%, P < 0.001), subgroup analyses were performed by
study design to elucidate the sources of the heterogeneity.
First, the studies were divided by randomisation status
(Figure 3B), where I2 values remained similar (96.9%). Then,
they were subgrouped by publication status (Figure 3C),
which did not reduce I2 values, but the pooled estimates of
the change in LVEF became significantly positive with 14%
[1.4, 26.6].
The cardiovascular mortality
Our secondary outcome, the combined endpoint of cardio-
vascular mortality or HTx, was assessed in a similar manner
(Figure 4A). Only one study demonstrated statistically signif-
icant prognostic improvement,12 with the rest showing neu-
tral results.3,4,21 The pooled RR was 0.34 [0.08, 1.51].
Because of a moderate heterogeneity (I2 = 60%), we
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performed subgroup analyses to assess the possible contrib-
utors. When categorised by randomisation or not, an I2
value significantly dropped close to low level (32%) with
no difference in the pooled RR of the RCTs (Figure 4B).
Subgrouping by publication status increased the heteroge-
neity, just missing the mark to be marked as ‘high’
(72.9%; Figure 4C).
Discussion
Statement of principal findings
Our results in the pooled analysis demonstrated that addi-
tional immunosuppression therapy with prednisone and aza-
thioprine (IPA) to current standard HF care did not improve
LVEF or clinical outcomes. However, when we limited the
studies published in the literature, there was a significant im-
provement in LVEF. Although not statistically significant, a
trend towards lower cardiovascular mortality or HTx was also
observed. The heterogeneity of this result was mitigated
when we analysed the clinical outcomes data from the RCTs
separately. Given large heterogeneity among the identified
studies, our results have to be interpreted carefully and
merely as hypothesis generating.
Strengths and weaknesses of the study
The strengths of this study were four-fold: (i) analysis of the
combination therapy of prednisone and azathioprine in addi-
tion to standard HF therapy in treating virus negative inflam-
matory positive cardiomyopathy, instead of accumulating the
evidence from variety of single or dual agents and myocardi-
tis in general; (ii) the use of surrogate (i.e. LVEF) combined
with clinical endpoints (aka cardiovascular mortality and
HTx-free survival); (iii) sound qualitative analysis with random
effect model and subgroup analysis, providing further insights
into the possible sources of heterogeneity; (iv) appropriately
evaluated risk of bias using recommended tools.
Strengths and weaknesses in relation to other
studies
There are two previous meta-analyses on this topic.17,25 Only
one showed improvement in EF using a fixed-effect model to
Figure 2 Funnel plots for publication bias. Publication bias was assessed using funnel plots. The weighted mean difference in EF (A) and (B). Cardio-
vascular mortality (C) and (D).
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Figure 3 Forest plots on the changes in LVEF. Forest plots on the changes of EF in three different settings: (A) all four studies, (B) subgrouped by study
design (RCT or not), and (C) subgrouped by publication status (published or not).
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Figure 4 Forest plots on cardiovascular mortality
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pool the estimate.25 Our findings support the positive trend
demonstrated in the second one,17 where, similar to our
analysis, a random effect model was used. The rationale be-
hind using the random effect model is that the true impact
of IPA would be distributed around a mean, which in this
analysis is because of the heterogeneity of trial design and
outcome measures. The previous two meta-analyses included
only RCT or quasi-RCT design studies, which provide better in-
ternal validity by the design per se at the cost of a smaller
sample size. We included one well-designed registry data
matched with propensity-matched controls,16 which included
the largest patient population so far, and also data from an
unpublished RCT,21 which added the largest sample size with
higher precision. This meta-analysis was not the first to ana-
lyse clinical endpoints. However, by using a larger sample
size, this study allowed investigators to appreciate the effects
of IPA on a larger scale.
Limitations
Our results should be interpreted in the following limitations.
Risk of bias within and across studies
Possible within-study risk of bias was identified in the unpub-
lished RCT,21 given the limited information provided by the
authors. Across studies, meta-bias was graphically assessed.
Significant asymmetrical distributions of studies observed in
the funnel plots of the change in LVEF suggests the possibility
of publication bias. However, the sporadic distribution made
it difficult or even futile to indicate where or which direction
the publication bias might sit. This was corroborated by the
difference in the centre lines of funnel and confunnel plots.
Because of the small number of studies identified, results of
this meta-analysis should be interpreted with caution.
Heterogeneity
We also found significant heterogeneity among the four iden-
tified studies. In LVEF outcome, 96.8% of the variability in the
point estimate is because of true heterogeneity rather than
sampling error. This is possibly related to the different IPA re-
gimes and inclusion criteria (see Table 1). Meta-regression
analysis was not performed because of the small number of
studies included. Furthermore, NNT was not explored be-
cause of neutral findings.
Future directions
According to this meta-analysis, additional immunosuppres-
sion therapy with IPA to current standard HF care in patients
with virus negative/auto-immune inflammatory cardiomyop-
athy can be considered. There is no sign of harm, and a po-
tential positive effect on both LVEF and clinical endpoints is
noted.26 Current practice will hardly be changed by this re-
sult, because the current guidelines on HF treatment are
based on quantification of LVEF, regardless of aetiology.2
However, a recent landmark trial27 is challenging the current
role of ICD implantations in non-ischemic HFrEF patients.28,29
Moreover, diagnosing a patient reliably as having a LVEF of
less than 35% is not as straightforward as previously
assumed.30 More aetiology-based therapeutic options are
therefore a promising lead into the future of HF research.31
Given the modifiable nature of the disease with favourable
findings in this meta-analysis, further well-designed and
adequately powered prospective RCTs in inflammatory car-
diomyopathies can elucidate the true impact of immunosup-
pression. To prevent further heterogeneity in the results of
such trials, the most promising medication scheme4,16 should
be adopted in order to assess the effect on functional out-
comes combined with an adequate and standardised
follow-up time to record an effect on clinical outcomes. Un-
fortunately, one such trial was aborted because of lack of
funding (INFLAMMACOR, see Appendix D).
Conclusions
There is currently insufficient evidence supporting functional
and prognostic benefits of combination therapy with predni-
sone and azathioprine to standard HF care in patients with in-
flammatory cardiomyopathy. However, given large
heterogeneity and small to midsized studies, future
well-designed prospective RCTs may explore the positive sig-
nal on LVEF and clinical outcomes associated with IPA to stan-
dard HF treatment that is demonstrated in this meta-analysis.
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Appendix A: Scientific search details
• Medline OVID
• Myocarditis
(exp Myocarditis/) OR (cardiomyopathies/ or exp cardiomy-
opathy, dilated/)
• Immunosuppresive
(exp Immunosuppressive Agents) OR (exp Steroids/) OR (exp
Prednisolone/) OR (exp Azathioprine/)
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Appendix B: Critical appraisal of the RCTs included in the meta-analysis using the
RoB 2.0 tool
B.1 Bias assessment of the Wojnicz paper
Domain Signalling questions Response options
Description/
support for
judgement
Bias arising from
the
randomisation
process
1.1 Was the allocation sequence random? Y / PY / PN / N / NI Y
NI1.2 Was the allocation sequence concealed
until participants were recruited and
assigned to interventions?
Y / PY / PN / N / NI
1.3 Were there baseline imbalances that
suggest a problem with the randomisation
process?
Y / PY / PN / N / NI N
Risk of bias judgement Low / High / Some
concerns
Some concerns
Optional: What is the predicted direction of
bias arising from the randomisation process?
Favours experimental /
Favours comparator /
Towards null /Away from
null / Unpredictable
Towards null
Bias because of
deviations from
intended
interventions
2.1. Were participants aware of their
assigned intervention during the trial?
Y / PY / PN / N / NI NI
NI
2.2. Were carers and trial personnel aware of
participants’ assigned intervention during
the trial?
Y / PY / PN / N / NI
2.3. If Y/PY/NI to 2.1 or 2.2: Were there
deviations from the intended intervention
beyond what would be expected in usual
practice?
NA / Y / PY / PN / N / NI N
2.4. If Y/PY to 2.3: Were these deviations
from intended intervention unbalanced
between groups and likely to have affected
the outcome?
NA / Y / PY / PN / N / NI
2.5 Were any participants analysed in a group
different from the one to which they were
assigned?
Y / PY / PN / N / NI N
2.6 If Y/PY/NI to 2.5: Was there potential for a
substantial impact (on the estimated effect
of intervention) of analysing participants in
the wrong group?
NA / Y / PY / PN / N / NI
Risk of bias judgement Low / High / Some
concerns
Some concerns
Optional: What is the predicted direction of
bias because of deviations from intended
interventions?
Favours experimental /
Favours comparator /
Towards null /Away from
null / Unpredictable
no
Bias because of
missing
outcome data
3.1 Were outcome data available for all, or
nearly all, participants randomised?
Y / PY / PN / N / NI PN
3.2 If N/PN/NI to 3.1: Are the proportions of
missing outcome data and reasons for
missing outcome data similar across
intervention groups?
NA / Y / PY / PN / N / NI PY
3.3 If N/PN/NI to 3.1: Is there evidence that
results were robust to the presence of
missing outcome data?
NA / Y / PY / PN / N / NI PN
Risk of bias judgement Low / High / Some
concerns
Some concerns
Optional: What is the predicted direction of
bias because of missing outcome data?
Favours experimental /
Favours comparator /
Towards null /Away from
null / Unpredictable
Y / PY / PN / N / NI PY
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B.2 Bias assessment of the Frustaci paper using the RoB 2.0 tool
Domain Signalling questions Response options
Description/
support for
judgement
Bias in
measurement of
the outcome
4.1 Were outcome assessors aware of the
intervention received by study participants?
4.2 If Y/PY/NI to 4.1: Was the assessment of
the outcome likely to be influenced by
knowledge of intervention received?
NA / Y / PY / PN / N / NI PY
Risk of bias judgement Low / High / Some
concerns
Some concerns
Optional: What is the predicted direction of
bias because of measurement of the
outcome?
Favours experimental /
Favours comparator /
Towards null /Away from
null / Unpredictable
Favours
experimental
Bias in selection
of the reported
result
Are the reported outcome data likely to have
been selected, on the basis of the results,
from…
N
5.1.…multiple outcome measurements (e.g.
scales, definitions, time points) within the
outcome domain?
Y / PY / PN / N / NI
5.2 … multiple analyses of the data? Y / PY / PN / N / NI N
Risk of bias judgement Low / High / Some
concerns
low
Optional: What is the predicted direction of
bias because of selection of the reported
result?
Favours experimental /
Favours comparator /
Towards null /Away from
null / Unpredictable
Overall bias Risk of bias judgement Low / High / Some
concerns
Some concerns
Optional:
What is the overall predicted direction of bias
for this outcome?
Favours experimental /
Favours comparator /
Towards null /Away from
null / Unpredictable
Favours
experimental
Domain Signalling questions
Response
options
Description/
support for
judgement
Bias arising from
the
randomisation
process
1.1 Was the allocation sequence random? Y / PY / PN / N / NI Y
Y1.2 Was the allocation sequence concealed
until participants were recruited and
assigned to interventions?
Y / PY / PN / N / NI
1.3 Were there baseline imbalances that
suggest a problem with the randomisation
process?
Y / PY / PN / N / NI N
Risk of bias judgement Low / High /
Some concerns
low
Optional: What is the predicted direction of
bias arising from the randomisation process?
Favours
experimental /
Favours
comparator /
Towards null /
Away from null /
Unpredictable
Towards null
Bias because of
deviations from
intended
interventions
2.1. Were participants aware of their
assigned intervention during the trial?
Y / PY / PN / N / NI N
N
2.2. Were carers and trial personnel aware of
participants’ assigned intervention during
the trial?
Y / PY / PN / N / NI
2.3. If Y/PY/NI to 2.1 or 2.2: Were there
deviations from the intended intervention
beyond what would be expected in usual
practice?
NA / Y / PY / PN /
N / NI
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Domain Signalling questions
Response
options
Description/
support for
judgement
2.4. If Y/PY to 2.3: Were these deviations
from intended intervention unbalanced
between groups and likely to have affected
the outcome?
NA / Y / PY / PN /
N / NI
2.5 Were any participants analysed in a group
different from the one to which they were
assigned?
Y / PY / PN / N / NI N
2.6 If Y/PY/NI to 2.5: Was there potential for a
substantial impact (on the estimated effect
of intervention) of analysing participants in
the wrong group?
NA / Y / PY / PN /
N / NI
Risk of bias judgement Low / High /
Some concerns
low
Optional: What is the predicted direction of
bias because of deviations from intended
interventions?
Favours
experimental /
Favours
comparator /
Towards null /
Away from null /
Unpredictable
Bias because of
missing
outcome data
3.1 Were outcome data available for all, or
nearly all, participants randomised?
Y / PY / PN / N / NI Y
3.2 If N/PN/NI to 3.1: Are the proportions of
missing outcome data and reasons for
missing outcome data similar across
intervention groups?
NA / Y / PY / PN /
N / NI
3.3 If N/PN/NI to 3.1: Is there evidence that
results were robust to the presence of
missing outcome data?
NA / Y / PY / PN /
N / NI
Risk of bias judgement Low / High /
Some concerns
low
Optional: What is the predicted direction of
bias because of missing outcome data?
Favours
experimental /
Favours
comparator /
Towards null /
Away from null /
Unpredictable
Bias in
measurement of
the outcome
4.1 Were outcome assessors aware of the
intervention received by study participants?
Y / PY / PN / N / NI N
4.2 If Y/PY/NI to 4.1: Was the assessment of
the outcome likely to be influenced by
knowledge of intervention received?
NA / Y / PY / PN /
N / NI
N
Risk of bias judgement Low / High /
Some concerns
low
Optional: What is the predicted direction of
bias because of measurement of the
outcome?
Favours
experimental /
Favours
comparator /
Towards null /
Away from null /
Unpredictable
Bias in selection
of the reported
result
Are the reported outcome data likely to have
been selected, on the basis of the results,
from…
N
5.1.…multiple outcome measurements (e.g.
scales, definitions, time points) within the
outcome domain?
Y / PY / PN / N / NI
5.2 … multiple analyses of the data? Y / PY / PN / N / NI N
Risk of bias judgement Low / High /
Some concerns
low
Optional: What is the predicted direction of
bias because of selection of the reported
result?
Favours
experimental /
Favours
comparator /
Towards null
(Continues)
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Domain Signalling questions
Response
options
Description/
support for
judgement
Towards null /
Away from null /
Unpredictable
Overall bias Risk of bias judgement Low / High /
Some concerns
low
Optional:
What is the overall predicted direction of bias
for this outcome?
Favours
experimental /
Favours
comparator /
Towards null /
Away from null /
Unpredictable
Appendix C: Bias assessment of the registry included in the meta-analysis using
the ROBINS-I tool
C.1 Bias assessment of the Merken paper using the ROBINS-I tool
Signalling questions Description Response options
Bias because of confounding
1.1 Is there potential for confounding of
the effect of intervention in this study?
If N/PN to 1.1: the study can be considered
to be at low risk of bias because of
confounding and no further signalling
questions need be considered
N (propensity
matching score)
Yes
Y / PY / PN / N
If Y/PY to 1.1: determine whether there is a
need to assess time-varying confounding:
1.2. Was the analysis based on splitting
participants’ follow-up time according to
intervention received?
If N/PN, answer questions relating to
baseline confounding (1.4 to 1.6)
If Y/PY, go to question 1.3.
Yes (cohort) NA / Y / PY / PN / N /
NI
1.3. Were intervention discontinuations
or switches likely to be related to factors
that are prognostic for the outcome?
If N/PN, answer questions relating to
baseline confounding (1.4 to 1.6)
If Y/PY, answer questions relating to both
baseline and time-varying confounding
(1.7 and 1.8)
No NA / Y / PY / PN / N /
NI
Questions relating to baseline confounding only
1.4. Did the authors use an appropriate
analysis method that controlled for all
the important confounding domains?
Yes NA / Y / PY / PN / N /
NI
1.5. If Y/PY to 1.4: Were confounding
domains that were controlled for
measured validly and reliably by the
variables available in this study?
Propensity matching,
thereby excluding
some patients
NA / Y / PY / PN / N /
NI
1.6. Did the authors control for any
post-intervention variables that could
have been affected by the intervention?
NI NA / Y / PY / PN / N /
NI
(Continues)
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Signalling questions Description Response options
Bias because of confounding
Questions relating to baseline and time-varying confounding
1.7. Did the authors use an appropriate
analysis method that controlled for all
the important confounding domains and
for time-varying confounding?
PN NA / Y / PY / PN / N /
NI
1.8. If Y/PY to 1.7: Were confounding
domains that were controlled for
measured validly and reliably by the
variables available in this study?
NA / Y / PY / PN / N /
NI
Risk of bias judgement low Low / Moderate /
Serious / Critical / NI
Optional: What is the predicted direction
of bias because of confounding?
Favours
experimental /
Favours
comparator /
Unpredictable
Bias in selection of participants into the study
2.1. Was selection of participants into the
study (or into the analysis) based on
participant characteristics observed after
the start of intervention?
If N/PN to 2.1: go to 2.4
NI Y / PY / PN / N / NI
2.2. If Y/PY to 2.1: Were the
post-intervention variables that
influenced selection likely to be
associated with intervention?
N NA / Y / PY / PN / N /
NI
2.3 If Y/PY to 2.2: Were the
post-intervention variables that
influenced selection likely to be
influenced by the outcome or a cause of
the outcome?
NA / Y / PY / PN / N /
NI
2.4. Do start of follow-up and start of
intervention coincide for most
participants?
Y Y / PY / PN / N / NI
2.5. If Y/PY to 2.2 and 2.3, or N/PN to 2.4:
Were adjustment techniques used that are
likely to correct for the presence of
selection biases?
NA / Y / PY / PN / N /
NI
Risk of bias judgement low Low / Moderate /
Serious / Critical / NI
Optional: What is the predicted direction
of bias because of selection of
participants into the study?
unpredictable Favours
experimental /
Favours
comparator /
Towards null /Away
from null /
Unpredictable
Bias in classification of interventions
3.1 Were intervention groups clearly
defined?
N Y / PY / PN / N / NI
3.2 Was the information used to define
intervention groups recorded at the start
of the intervention?
Y Y / PY / PN / N / NI
3.3 Could classification of intervention
status have been affected by knowledge
of the outcome or risk of the outcome?
PY Y / PY / PN / N / NI
Risk of bias judgement moderate Low / Moderate /
Serious / Critical / NI
Optional: What is the predicted direction
of bias because of classification of
interventions?
unpredictable Favours
experimental /
Favours
comparator /
Towards null /Away
(Continues)
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Signalling questions Description Response options
Bias because of confounding
from null /
Unpredictable
Bias because of deviations from intended interventions
If your aim for this study is to assess the effect of assignment to intervention,
answer questions 4.1 and 4.2
4.1. Were there deviations from the
intended intervention beyond what
would be expected in usual practice?
N Y / PY / PN / N / NI
4.2. If Y/PY to 4.1: Were these deviations
from intended intervention unbalanced
between groups and likely to have
affected the outcome?
NA / Y / PY / PN / N /
NI
If your aim for this study is to assess the effect of starting and adhering to
intervention, answer questions 4.3 to 4.6
4.3. Were important co-interventions
balanced across intervention groups?
N
Y / PY / PN / N / NI
4.4. Was the intervention implemented
successfully for most participants?
Y
Y / PY / PN / N / NI
4.5. Did study participants adhere to the
assigned intervention regimen?
NI Y / PY / PN / N / NI
4.6. If N/PN to 4.3, 4.4 or 4.5: Was an
appropriate analysis used to estimate the
effect of starting and adhering to the
intervention?
N
NA / Y / PY / PN / N /
NI
Risk of bias judgement Moderate (no info on
drug adherence)
Optional: What is the predicted direction
of bias because of deviations from the
intended interventions?
Favours comparator
(=OMT without
immunosuppression)
Bias because of missing data
5.1 Were outcome data available for all, or
nearly all, participants?
Y Y / PY / PN / N / NI
5.2 Were participants excluded because of
missing data on intervention status?
N Y / PY / PN / N / NI
5.3 Were participants excluded because of
missing data on other variables needed for
the analysis?
PN Y / PY / PN / N / NI
5.4 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Are
the proportion of participants and reasons
for missing data similar across
interventions?
NA / Y / PY / PN / N /
NI
5.5 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Is
there evidence that results were robust to
the presence of missing data?
NA / Y / PY / PN / N /
NI
Risk of bias judgement low Low / Moderate /
Serious / Critical / NI
Optional: What is the predicted direction
of bias because of missing data?
Favours
experimental /
Favours
comparator /
Towards null /Away
from null /
Unpredictable
Bias in measurement of outcomes
6.1 Could the outcome measure have
been influenced by knowledge of the
intervention received?
PY (for
echocardiographic
measurements) – not
for mortality or HTx!
Y / PY / PN / N / NI
6.2 Were outcome assessors aware of the
intervention received by study
participants?
PY (for
echocardiographic
measurements) – not
for mortality or HTx!
Y / PY / PN / N / NI
(Continues)
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Signalling questions Description Response options
Bias because of confounding
6.3 Were the methods of outcome
assessment comparable across
intervention groups?
Y Y / PY / PN / N / NI
6.4 Were any systematic errors in
measurement of the outcome related to
intervention received?
N Y / PY / PN / N / NI
Risk of bias judgement Moderate (for EF) –
low for mortality or
HTx!
Low / Moderate /
Serious / Critical / NI
Optional: What is the predicted direction
of bias because of measurement of
outcomes?
Favours experitmental Favours
experimental /
Favours
comparator /
Towards null /Away
from null /
Unpredictable
Bias in selection of the reported result
Is the reported effect estimate likely to be
selected, on the basis of the results,
from…
N
7.1. … multiple outcome measurements
within the outcome domain?
Y / PY / PN / N / NI
7.2 … multiple analyses of the
intervention-outcome relationship?
N Y / PY / PN / N / NI
7.3 … different subgroups? N Y / PY / PN / N / NI
Risk of bias judgement low Low / Moderate /
Serious / Critical / NI
Optional: What is the predicted direction
of bias because of selection of the
reported result?
Favours
experimental /
Favours
comparator /
Towards null /Away
from null /
Unpredictable
Overall bias
Risk of bias judgement Moderate; choice of
immunnosuprression
therapy in treatment
group is not stated,
but baseline
characteristics are
matched. There is
likely bias for
echocardiographic
measurements
because patients nor
operators were not
blinded.
Low / Moderate /
Serious / Critical / NI
Optional: What is the overall predicted
direction of bias for this outcome?
Favours
experimental /
Favours
comparator /
Towards null /Away
from null /
Unpredictable
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Appendix D: The INFLAMMACOR project
The INFLAMMACOR trial a project managed by the cardiomyopathy research team at the Maastricht University (the
Netherlands) and is planned with a prospective randomised open-label blinded end-point (PROBE) design. Target group are
patients with a biopsy proven inflammatory non-ischemic non-valvular cardiomyopathy not responding to conventional optical
medical therapy after 3 months. The syndrome is defined as follows:
• LVEF ≤ 40% (also non-dilated) despite optimal HF therapy for 3 months
• Non-significant viral load (<500 copies per microgram DNA, PVB19, HHV4, and HHV6)
• EMB: CD45 ≥ 14 with the presence of up to 4 CD68 or CD3 ≥7 cells/mm2
The intervention is the addition of a combined immunosuppressive treatment for 6 months on top of conventional heart
failure drugs. The dose regime consists of prednisone (1 mg/kg/day first 4 weeks, 0.33 mg/kg/day afterwards) and azathio-
prine (2 mg/kg/day).
The primary endpoint is the change in LVEF after 6 and 12 months as assessed with echocardiography. Secondary endpoint
is a combined endpoint of overall mortality, (cardiovascular) hospitalisation, heart transplantation, ICD shocks/resuscitation,
NYHA class, LV chamber dimensions (LVEDD, LVESD), (opportunistic) infections, 6-min walking distance, Minnesota Living With
Heart Failure score.
A total of 80 patients (40 in both groups) are needed according to the power calculation of the study to measure a differ-
ence in the primary outcome. Seven hospitals across the Netherlands and Belgium have committed to participate.
D.1 List of participating centres for the INLAMMACOR project
Hospital Country Principal investigator(s)
Maastricht University Medical Centre NL Stephane Heymans
Groningen University Medical Centre NL Rudolf de Boer
OLV Aalst B Ward Heggermont
Jessa Hospital Hasselt B Philippe Timmermans, Paul Dendale
University Hospital Antwerp (UZA) B Constantijn Franssen, Emeline van Craenenbroeck
University Hospital Louvain (UCL) B Anne Catherine Pouleur
University Hospital Liège (CHL, ‘Citadelle’) B Pierre Troisfontaines
B, Belgium; NL, the Netherlands.
Funding is originally requested at the BeNeFit organisation (https://kce.fgov.be/nl/benefit-2018) but unfortunately not
granted. Other sources of funding are currently being searched.
Upon contacting the research team at St. Anne’s University Hospital Brno, Czech Republic regarding their experience and
data of the CZECH-ICIT study, renewed interest in participation in a clinical trial was shown. The researchers contacted the
PI at the Maastricht University for further collaboration and participation in the INFLAMMACOR project.
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